Product Development Stories

Approximately 15.0% of Aqua Metals shares are held by institutions, such as insurance companies. Insider ownership of Aqua Metals refers to the portion of Aqua Metals equity owned by the company's officers, directors, leadership team relatives, or anyone with access to non-public information. For our latest analysis of Aqua Metals, including its current ownership diagnostics, please check out our most recent report.

Progressive assessment

Aqua Metals, a company operating in the industrials sector with a specific focus on waste management, presents an intriguing investment opportunity.

Archer Aviation (ACHR.US), a key player in the Aerospace & Defense industry, offers an exciting investment opportunity for retail investors. Despite a negative earnings per share of $1.62, indicating a loss, the company has a strong buy consensus from five analysts, suggesting a positive future outlook. Archer Aviation's stock is currently undervalued with a real value of $6.95, compared to the analyst target price estimated value of $8.64.

Rhythm Pharmaceuticals (NASDAQ: RYTM), a key player in the Biotechnology industry, continues to exhibit bullish momentum in the US stock market. Despite reporting a net income loss of $181.1M and a diluted EPS of -3.38, the company's market capitalization stands at a robust $1.3B, with an enterprise value of $721.5M. The company, which operates in the Healthcare sector, specifically in Pharmaceuticals, Biotechnology & Life Sciences, has seen a quarterly revenue growth of 6.66%, bringing in revenues of $33.6M.

Powell Industries (POWL), a leading player in the Capital Goods sector and Electrical Equipment service category, has been a standout performer, defying the modest market downturn. With a market capitalization of $726.9M, Powell Industries has managed to maintain a robust operating margin of 3.75%, demonstrating the company's efficiency in operations. The company's EBITDA stands at $31.2M, and it has reported a net interest income of $334K.

Cardlytics (NASDAQ: CDLX), a prominent player in the Communication Services sector and the Advertising Agencies industry, continues to maintain its upward momentum in the US stock market. Despite a challenging fiscal year ending in December, marked by a loss of $465.3 million from continuing operations and a profit margin of -1.64%, the company has managed to sustain its market position. With an enterprise value of $522.6 million, Cardlytics' resilience is noteworthy.

UroGen Pharma (URGN.US), a key player in the healthcare sector, specifically within the biotechnology and pharmaceuticals industry, has been under the radar of investors for a while now. The company, with an enterprise value of 543.3M, has been operating at a loss with a net income from continuing operations standing at 109.8M and an operating margin of -1.16. Despite the negative return on assets of -0.35 and return on equity of -14.81, the company has managed to generate an interest income of 938K.

View Inc., a key player in the Industrials sector and specifically within the Building Products & Equipment industry, is currently facing a challenging financial landscape. The company, which specializes in Industrial Machinery, has been grappling with a significant net income loss of $337.1M and an EBITDA of -$282.1M. Despite a quarterly revenue growth of 7.9%, the firm's operating margin stands at -2.98, reflecting operational inefficiencies.

Agilent Technologies, a prominent player in the Healthcare sector and specifically in the Life Sciences Tools & Services category, has seen its stock (USA Stocks:A) surge over 4% despite a slight market downturn. This international/domestic company, listed on the NYSE, boasts a robust enterprise value of $37.7B and a market capitalization matching its enterprise value. Agilent's financial health is evident in its impressive operating margin of 25.11% and a profit margin of 19.19%.

Agilent Technologies (A) is a leading player in the Healthcare Equipment & Supplies industry, with a focus on Pharmaceuticals, Biotechnology & Life Sciences. The company's strong product portfolio is one of the key factors driving its financial performance. It has an impressive operating margin of 25.11%, which is a testament to its efficient operations and strong pricing power.

Adamis Pharma, a key player in the Drug Manufacturers-Specialty & Generic industry, is worth considering for its product potential. Despite a reported net income loss of 26.2M from continuing operations, the company's enterprise value stands at a robust 917.6K, suggesting underlying value in its product portfolio. The stock has seen a minor price change of 0.03 recently, indicating stability in the market.